SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Conflicting reports around Nvidia's 18A chip engagement are central to Intel's trending discussion, with many dismissing negative news as FUD and a "hit piece." The community expresses strong conviction in Intel's foundry turnaround, buoyed by US antitrust clearance for Nvidia's substantial investment and a significant partnership with the Department of Energy for AI scientific discovery. This optimism prevails despite perceived market manipulation and frustration over recent price action.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

OMER is trending on high anticipation for an imminent FDA approval decision for its drug Narsoplimab, targeting a deadly disease with no approved treatments. The community is buzzing with speculation around a potential "Christmas miracle" approval, fueled by the company's recent strategic partnership with Novo Nordisk and strong clinical data, anticipating a significant short squeeze and a re-rating of the stock's value despite past regulatory hurdles.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending with high excitement following the successful orbital deployment of its BlueBird 6 satellite, a pivotal step towards delivering 5G connectivity directly to standard smartphones globally. The community views this milestone as a validation of ASTS's direct-to-device vision and a significant catalyst for future growth, generating widespread bullish sentiment and discussions about its long-term potential in the space sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as it prepares for inclusion in the S&P MidCap 400 index, a development expected to enhance its institutional visibility and liquidity. The community is actively discussing the potential for increased buying pressure from index funds and sees this as a significant validation. Many are also comparing UiPath to other rapidly growing AI stocks, recognizing its leadership in the Agentic AI and automation space.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust is surging to new all-time highs, driven by intensifying industrial demand from rapidly expanding sectors like AI data centers, EVs, and solar, alongside significant global supply concerns. The rally is further fueled by China's impending export restrictions on silver, with market participants eagerly discussing a potential 'silver squeeze' and a fundamental re-evaluation of its value, though some anticipate a near-term correction after its rapid ascent.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following FDA approval of AQVESME (mitapivat) for thalassemia-associated anemia, marking the first oral medicine for this patient population. This significant regulatory milestone is driving conversations about its commercial opportunity, though community sentiment remains polarized due to prior delays in regulatory decisions and mixed clinical trial results for other indications. Discussions are ongoing regarding the drug's market potential and the broader implications for the company's trajectory amidst persistent concerns about past management decisions and overall stock performance.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending significantly due to an agreement for its acquisition by Sanofi through a cash buyout offer. This news is driving widespread community discussion, with many long-term investors expressing both relief and some frustration over the valuation after years of minimal stock appreciation, as Sanofi aims to enhance its adult immunization portfolio with Dynavax's vaccine assets and adjuvant technology.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. ($FJET) is experiencing extreme volatility as a recent low-float IPO, captivating traders with its explosive price discovery. The community is debating its potential for a short squeeze against concerns about long-term fundamentals and market manipulation, positioning it as a high-risk, high-reward meme stock within the broader aerospace sector.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid starkly divided community sentiment, with many holders expressing frustration over current price levels and labeling it a "scam" or "dead" project. However, a passionate segment of the community remains highly confident, viewing this period as a key accumulation opportunity and anticipating a significant rally. This intense polarization and active debate around its future are driving conversations.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intense shareholder frustration over leadership's perceived inaction on securing a major partnership for its differentiated non-mRNA vaccine assets, particularly following a competitor's recent acquisition at a substantial premium. The community is buzzing with speculation that an anticipated 'black box' warning for mRNA vaccines could significantly re-evaluate Novavax's market position, alongside ongoing pressure for a strategic buyout from activist investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings...

Biomea Fusion (NASDAQ:BMEA) Price Target Cut to $6.00 by Analysts at Citigroup

Citigroup reduced their price objective on Biomea Fusion from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Monday...

Biomea Fusion FY2025 EPS Estimate Lowered by HC Wainwright

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - HC Wainwright lowered their FY2025 EPS estimates for Biomea Fusion in a research note issued on Wednesday, November 5th. HC Wainwright analyst J...

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Moderate Buy" by Analysts

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat.com reports. One...

Biomea Fusion (NASDAQ:BMEA) Given New $12.00 Price Target at D. Boral Capital

D. Boral Capital dropped their price target on shares of Biomea Fusion from $16.00 to $12.00 and set a "buy" rating on the stock in a research note on Wednesday...

Shares of Biomea Fusion drew heightened attention from retail investors on Tuesday after the company disclosed a public offering of its common stock and warrants.&nbsp;The stock closed up 10.3% at $2.9 on Tuesday but dropped 24.8% to $2.18 in after-hours trading.The offer includes shares, pre-funded warrants in place of shares to certain investors and accompanying warrants for the purchase of shares.Biomea said it will also give the underwriters a 30-day option to buy up to 15% more shares and pre-funded warrants. Jefferies is the sole book running manager.The offering is being made under a shelf registration and is expected to close on or around June 20, subject to customary closing conditions.&nbsp;Biomea said the completion, size, and terms of the offering are subject to market conditions and are not guaranteed.The offering comes just days after Biomea Fusion reported updated data from its Phase I Covalent 103 trial of BMF-500 in relapsed or refractory acute leukemia.&nbsp;The study, presented at the European Hematology Association Congress, showed early signs of clinical benefit in heavily pretreated patients with FLT3 mutations.&nbsp;The company said it plans to conclude internal development of BMF-500 in oncology and is exploring strategic partnerships to advance the program.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user said the raise could bring in around $30 million and&nbsp;added that while the added dilution might pressure the stock short-term, the reduced risk could unlock further upside, predicting a return above $3 in the coming weeks.&nbsp;<stembedurl>https://stocktwits.com/hashbridges/message/618219066</stembedurl>Another user expressed disappointment at the timing of the offering, saying they anticipated it at a higher price and would now hold the stock through year-end.<stembedurl>https://stocktwits.com/aquira/message/618214880</stembedurl>The stock has declined 21.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead

The offering follows early clinical data from Biomea’s BMF-500 leukemia program, which showed encouraging responses in heavily pretreated patients. 

Equity

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know

Shares of Biomea Fusion attracted significant retail attention on Tuesday after H.C. Wainwright reduced its price target for the stock to $18 from $40, while maintaining a ‘Buy’ rating.&nbsp;The&nbsp;reduction followed the company’s first-quarter earnings report, where Biomea unveiled a strategic shift to focus on its core diabetes and obesity programs.&nbsp;As part of its strategy, Biomea has implemented a cost-reduction initiative, which includes a workforce reduction of nearly 35% to reduce overall operating expenses and extend its cash runway into Q4 2025.The firm also removed type 1 diabetes from its projections and pushed the launch of icovamenib for type 2 diabetes to 2031 from the previously anticipated 2029.Biomea’s stock price declined by 16.5%, closing at $1.67 on May 6, 2025. However, it rebounded slightly in after-hours trading, increasing by 1.74% to $1.70.Retail sentiment surged on Stocktwits, where sentiment was ‘bearish’ views amid a 1,400% uptick in message volume.&nbsp;The sentiment seemed to reflect speculation about the company’s next moves and the market’s potential reactions.One user questioned the company’s decision to delay share dilution when the stock was priced at $4 earlier this year, suggesting that the current price of $1.60 might not align with Biomea’s broader plans, hinting that something was amiss.&nbsp;<stembedurl>https://stocktwits.com/NGEA/message/613687181</stembedurl>Meanwhile, another user speculated that Biomea's recent actions could indicate a “short trap” and accumulation of shares ahead of potential positive news.&nbsp;The user pointed out that despite concerns of running out of cash, Biomea had not raised funds through share sales but instead reduced its workforce to stretch its runway.<stembedurl>https://stocktwits.com/NGEA/message/613678729</stembedurl>In its Q1 update, interim CEO Mick Hitchcock highlighted the company’s efforts to prioritize high-value opportunities, extend its cash runway, and maintain its focus on icovamenib and BMF-650.&nbsp;Biomea also reported a Q1 net loss of $29.3 million, with cash reserves of $36.2 million, expected to fund operations until Q4 2025.Shares of Biomea have fallen 54.7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Biomea Fusion's Stock Plummets After Price Target Cut — Bearish Retail Traders Speculate Next Moves

Biomea Fusion is realigning its focus on diabetes and obesity programs, cutting 35% of its workforce and consolidating operations to reduce costs. 

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

BMEA
Biomea Fusion Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMEA News

BMEABiomea Fusion Inc